Addressing soaring prescription drug prices is a health care reform priority in the United States.1 While the pricing practices of pharmaceutical companies have been a subject of intense scrutiny and reform proposals, so have the practices of pharmacy benefit managers (PBMs), who are intermediaries in the drug supply chain.2
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Royce TJ, Kircher S, Conti RM. Pharmacy Benefit Manager Reform: Lessons From Ohio. JAMA. 2019;322(4):299–300. doi:10.1001/jama.2019.7104
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: